8:25 am Chair’s Opening Remarks

  • Cara Williams Vice President, Head of Preclinical Biology, Inflammation, & Immunology, Pfizer

Exploring Predictors of Progression to Define & Identify Progressive Fibrosis Phenotypes For Effective ILD Therapeutic Strategies

8:30 am Panel Discussion – What is PPF? Delving into Defining Progression to Illuminate Research & Therapeutic Development for Progressive Fibroses

  • Anna Podolanczuk Assistant Professor - Pulmonary & Critical Care Medicine, Weill Cornell - Cornell University
  • Resat Cinar Co-Chief of Fibrotic Diseases, The National Institutes of Health


  • What does early disease progression look like? Diagnosing progressing fibrosis using ideological and histopathological features
  • Illuminating the potential opportunity for early-stage diagnosis to target a specific subset of patients
  • Conducting longitudinal studies to screen CT-ILDs to understand progression
  • Deliberating the pros and cons of widening the patient population to PPF

9:00 am Using Artificial Intelligence (AI) Techniques to Create an Estimate of Interstitial Lung Disease Progression


  • Highlighting the real-world data available to implement imaging biomarkers in clinical trials
  • Assessing the imaging tools that are available for fibrotic ILD, PPF, & IPF
  • Moving towards imaging as a phase 3 endpoint

9:30 am Illuminating Biomarker Discovery in Systemic Sclerosis Associated ILD to Understand the Similarities to IPF

  • Xia Gao Biomarker Scientist, Genentech


  • Understanding PD biomarkers and MOA of Acterma in Phase III clinic trail for SSc-ILD patients
  • Identifying novel biomarkers involved in lung and skin pathology of SSc patients by serum and tissue proteomics
  • Discussing the biomarkers involved in different pathophysiology which may be potential used for clinic trails targeted for different biology

10:00 am Implementing a Precision Medicine Model to Stratify SSc-ILD Patients for 12 Months Risk of Progression


  • Identifying a clinical-biomarker combined model of PF-SSc ILD
  • Optimizing screening algorithms to maximise clinical efficiency
  • Applying the model in a clinical trial setting

10:30 am Speed Networking


This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the interstitial lung disease field. Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into the pioneering research and therapeutic development.

11:15 am Morning Break


Grab a coffee & refresh before the next presentations and sessions

11:30 am Identifying Scar-Associated Macrophages as Therapeutic Targets & Potential Biomarkers in Progressive Fibrosis

  • Kevin Hart Associate Research Fellow (Scientific Director) - Fibrosis Exploratory Biology & Drug Discovery, Pfizer


  •  Single cell transcriptomic analysis of human and murine fibrotic disease sample to identify key pathogenic cell subsets
  • Spatial Validation of Scar-associated macrophages present in fibrotic regions
  • Identification of key cytokine regulators and functions of Scar-associated macrophages

12:00 pm Targeting Macrophages to Create a Pro-Homeostatic Niche for Management of Fibrotic Disease

12:30 pm Lunch

1:30 pm Uncovering the Role of Monocytes & Tissue Macrophages Across Fibrotic ILDs to Illuminate the Key Predictors of Progression

  • Harris Perlman Professor & Chief of Rheumatology, Northwestern University


  • Assessing the transcriptional profile of monocytes correlating with scleroderma disease
  • Applying SSc-ILD monocyte-derived macrophages understanding to progressive pulmonary fibrosis
  • Devising a precision medicine approach to treat interstitial lung disease

2:00 pm Exploring the Role of Autoantibodies to Predict Outcomes of SSc-ILD


  • Understanding the protective vs. risk of progression in ILDs and the role of autoimmunity in CTD-ILD
  • Highlighting enrichment for clinical trials

2:30 pm Panel Discussion: Building a Biomarker Strategy for Effective Diagnostic, Predictive, & Prognostic Assessment Across ILDs

  • George Washko Professor of Medicine, Harvard Medical School  
  • Sydney Montessi Assistant Professor of Medicine, Massachusetts General Hospital
  • David Lynch Radiologist, National Jewish Health
  • Harris Perlman Professor & Chief of Rheumatology, Northwestern University


  • Biomarkers for interstitial lung abnormalities to look towards prevention
  • Imaging to predict progression and PPF for patient stratification and trial design
  • Exploring IPF and ILD clinical trial design using biomarkers and imaging

3:00 pm Poster Session & Afternoon Break


Connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships, whilst exploring the latest PPF and ILD drug development and research advancements.

To submit a poster or to find out more, contact info@hansonwade.com

Utilizing Novel Secondary & Exploratory Phase 3 Endpoints in Clinical Trial Design to Highlight Therapeutic Efficacy Across ILDs

4:00 pm Employing PET Probes in Early Phase Clinical Trials: From Target Engagement to Proof-Of-Concept

  • Sydney Montessi Assistant Professor of Medicine, Massachusetts General Hospital


  • Reviewing specific targets and probes to understand molecule distribution and activity related to pulmonary fibrosis
  • Understanding the strengths and weaknesses of employing PET imaging as part of clinical trial design
  • Using PET as an effective translational tool for early phase clinical trials in pulmonary fibrosis

4:30 pm Honing an AI/Quantitative Method to Access the Accumulating Morphological & Clinical Imaging Knowledge for Clinical & Technical Practice

  • George Washko Professor of Medicine, Harvard Medical School  


  • Using a CT algorithm to describe the molecular and genetic components simultaneously for disease characterisation
  • Applying the morphological and clinical imaging knowledge to a real-world patient population

5:00 pm Roundtable Discussions: Building a Biomarker Strategy for Effective Diagnostic, Predictive, & Prognostic Assessment Across ILDs

Understanding biomarkers for diagnostic and predictive assessment of fibrotic ILDs

Evaluating the immunological response after the start of antifibrotic treatment using proteomic approaches

Evaluating a range of prognostic biomarkers to evaluate the pros and cons during treatment

Biomarkers of predictive response to antifibrotic treatment

Comparing the similarities and differences of biomarkers across fibrotic ILDs

Predictors of a ‘good’ response to antifibrotics

5:30 pm Chair’s Closing Remarks